| Drug type | Project Code | Indication | Formulation | Preclinical | Phase 1 | Phase 2 | Phase 3 | MA |
|---|---|---|---|---|---|---|---|---|
| IMDs | AD-201 | Hyperlipidemia/Hypertension |
|
|||||
| IMDs | AD-202 | Hyperlipidemia/Hypertension |
|
|||||
| IMDs | AD-203 | Ulcer treatment |
|
|||||
| IMDs | AD-204 | Diabetes mellitus |
|
|||||
| IMDs | AD-205 | Hyperlipidemia |
|
|||||
| IMDs | AD-206 | GERD |
|
|||||
| IMDs | AD-207 | Hyperlipidemia/Hypertension |
|
|||||
| IMDs | AD-208 | Alopecia |
|
|||||
| IMDs | AD-209 | Hypertension |
|
|||||
| IMDs | AD-210 | Hypertension |
|
|||||
| IMDs | AD-211 | Pain treatment |
|
|||||
| IMDs | AD-212 | GERD |
|
|||||
| IMDs | AD-213 | GERD |
|
|||||
| IMDs | AD-214 | GERD |
|
|||||
| IMDs | AD-215 | Ulcer treatment |
|
|||||
| IMDs | AD-216 | Hyperlipidemia |
|
|||||
| IMDs | AD-217 | Hyperlipidemia |
|
|||||
| IMDs | AD-218 | Hyperlipidemia |
|
|||||
| IMDs | AD-219 | Type 2 diabetes/Hypertension |
|
|||||
| IMDs | AD-220 | Hyperlipidemia |
|
|||||
| IMDs | AD-221 | Hyperlipidemia |
|
|||||
| IMDs | AD-222 | Type 2 diabetes/Hypertension |
|
|||||
| Phase I Drugs | AD-101 | Postmenopausal osteoporosis |
|
|||||
| Phase I Drugs | AD-102 | Postmenopausal osteoporosis |
|
|||||
| Phase I Drugs | AD-103 | Hyperlipidemia |
|
|||||
| Phase I Drugs | AD-104 | Hyperlipidemia |
|
|||||
| Phase I Drugs | AD-106 | Alopecia |
|
|||||
| Phase I Drugs | AD-107 | Hypertension |
|
|||||
| Phase I Drugs | AD-108 | Hypertension |
|
|||||
| Phase I Drugs | AD-109 | Anticoagulant |
|
|||||
| Phase I Drugs | AD-110 | Hypertension |
|
|||||
| New Drugs | AD-301 | NASH |
|
|||||
| New Drugs | AD-302 | Pain treatment |
|